Reproductive system of women with acromegaly
https://doi.org/10.14341/brh2011132-39
Abstract
192 patients with acromegaly were examined. Their reproductive disorders were found to be a result of the suppressed synthesis of gonadotropin hormones due to the tumor compression of the adenohypophysis, due to blocking effect of hyperprolactinemia on the gonadotropic function or as a result of the direct impact of insulin-like growth factor-I stimulating hyperplastic processes in target organs, such as ovaries, the glandular epithelium of the breast and myometrium. The structure of reproductive disorders in patients with acromegaly includes menstrual disturbances, infertility, early menopause and hyperplastic processes. Close management of the reproductive system, early detection of neoplasia and correction of the existing disorders are highly required during therapy for acromegaly.
About the Authors
A V Pronin
First Moscow State Medical University, Moscow, Russia
A P Kirjushchenkov
First Moscow State Medical University, Moscow, Russia
G A Melnichenko
First Moscow State Medical University, Moscow, Russia
I D Hohlova
First Moscow State Medical University, Moscow, Russia
E V Fedorova
First Moscow State Medical University, Moscow, Russia
V S Pronin
First Moscow State Medical University, Moscow, Russia
E P Gitel
First Moscow State Medical University, Moscow, Russia
References
1. Ezzat S, Asa SL, Couldwell WT et al. The prevalence of pituitary adenomas: a systematic review. Cancer 2004; 101: 613-619.
2. Patil CG, Hayden, L. Katznelson et al. Non-surgical management of hormone-secreting pituitary tumors. J Clin Neurosci 2009; 16: 985-993.
3. Melmed S, Casanueva FF, Cavagnini F et al. Consensus Guidelines for Acromegaly Management J Clin Endocr Metab 2002: 87: 4054-4058.
4. Horvath E, Kovacs K. Pathology of Acromegaly. Neuroendocrinology. 2006; 83: 161-165.
5. Sekizawa N, Hayakawa E, Tsuchiya K et al. Acromegaly Associated with Multiple Tumor. Inter Med 2009; 48: 12731278.
6. Di Chiro G, Nelson KB. The volume of the sella turcica. Am J Radiol 1962; 87: 989-1008.
7. Федорова Е.В. Возможности транвагинальной эхографии, цветового допплеровского картирования и допплерометрии в диагностике гиперпластических процессов эндометрия и оценке эффективности проводимого лечения. Дис….канд. мед. наук. М., 2000.
8. Коколина В.Ф. Детская и подростковая гинекология. М.: Медпрактика-М, 2006; 300-301.
9. Бесплодный брак. Современные подходы к диагностике и лечению. Под ред. В.И. Кулакова. М.: ГэотарМедиа, 2006; 126-128
10. Bigazzi M, Ronga R, Lacranjan I et al. A pregnancy in an acromegalic woman during bromocriptine treatment: effects on growth hormone and prolactin in the maternal, fetal and amniotic compartments. J Clin Endocrinol Metab 1979; 48:9.
11. Montini M, Pagani G, Gianola D et al. Acromegaly and primary amenorrhea: Ovaluation and pregnancy induced by SMS 201–995 and bromocriptine [Letter]. J Endocrinol Invest 1990; 13:193.
12. Fassnacht M, Capeller B, Arlt W et al. Octreotide LAR treatment throughout pregnancy in an acromegalic woman. Clin Endocrinol (Oxf) 2001; 55(3):411-5.
13. Menis E, Billeci D, Marton E. Uneventful Pregnancy in an Acromegalic Patient Treated with Slow-Release Lanreotide: A Case Report. J Clin Endocrinol & Metabol, 1999; 84(4): 1489.
14. Dreval A, Pokramovich J, Nechaeva O. Pregnancy and childbirth in active acromegaly patient treated with long acting somatostatin analogue. European Congress of Endocrinology 2009. Istanbul, Turkey. 25 April 2009 29 April 2009, 20 P175.
15. Cozzi R, Attanasio R, Barausse M. Pregnancy in acromegaly: a one-center experience. Eur J Endocrinol 2006; 155(2):279-84.
16. Takano T, Saito J, Soyama A et al. Normal delivery following an uneventful pregnancy in a Japanese acromegalic patient after discontinuation of octreotide long acting release formulation at an early phase of pregnancy. Endocr J 2006; 53(2):209-12.
17. Мельниченко Г.А., Соснова Е.С., Романцова Т.И. Восстановление репродуктивной функции при гиперпролактинемическом гипогонадизме. Акуш и гин 2001; 3: 36-39
18. Мельниченко Г.А., Пронин В.С., Колода Д.Е. и др. Место аналогов соматостатина в комбинированном лечении синдрома избыточной продукции гормона роста. М., 2008; 37-57.
19. Popovic V, Damjanovic S, Micic D et al. Increased incidence of neoplasia in patients with pituitary adenomas. The Pituitary Study Group. Clin Endocrinol (Oxf) 1998; 49:441-445.
20. Вихляева Е.М. О стратегии и тактике ведения больных с миомой матки. Вестн. Рос. ассоц. акуш.гинек. 1997; 3: 21-23.
21. Aleem F, Pennisi J, Zeitoun K. The role of color Doppler in diagnosis of endometriomas. Ultrasound Obstet Gynecol 1995; 5(1): 51-4.
22. Сидоренко Л.М. Мастопатия. Л., 1991.
23. Швецова О.Б. Гинекология. 2000; 2(5): 43-46.
24. Mercе LT, Lopez Garc a G, de la Fuente F. Doppler ultrasound assessment of endometrial pathology. Acta Obstet Gyn Scand. 1991; 70(7-8): 525-30.
25. Advis JP, White SS, Ojeda SR. Activation of growth hormone short loop negative feedbak delays puberty in the female rat. Endocrinology. 1981; 108:1343–1352.
26. Molitch ME. Pregnancy and hyperprolactinemic women. N Engl J Med 1985; 312:1364–1370.
Review
For citations:
Pronin A.V., Kirjushchenkov A.P., Melnichenko G.A., Hohlova I.D., Fedorova E.V., Pronin V.S., Gitel E.P. Reproductive system of women with acromegaly. Bulletin of Reproductive Health. 2011;(1):32-39. (In Russ.) https://doi.org/10.14341/brh2011132-39
Views:
433
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
